PAR Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Paradigm Biopharmaceuticals Ltd

Watchlist Manager

Watchlist

Price: 0.175 AUD 9.37%

Market Cap: AU$100.9m

	Paradigm Biopharmaceuticals Ltd ASX:PAR	AU
	Centessa Pharmaceuticals PLC NASDAQ:CNTA	UK
L	Lynas Rare Earths Ltd DUS:LYI	AU

Profitability Summary

Paradigm Biopharmaceuticals Ltd's profitability score is 19/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

100%

Strong 3Y Average Gross Margin

100%

Gross Margin is Increasing

100% > 100%

Negative Operating Margin

-495%

Negative 3Y Average Operating Margin

-563%

Operating Margin is Increasing

-608% > -495%

Negative Net Margin

-519%

Negative 3Y Average Net Margin

-574%

Net Margin is Increasing

-611% > -519%

Negative Free Cash Flow Margin

-230%

Negative 3Y Average Free Cash Flow Margin

-672%

Free Cash Flow Margin is Increasing

-532% > -230%

Negative ROE

-180%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-2 081%

ROIC is Increasing

-4 283% > -492%

View All

Hide

Collapse

19 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

100%

Strong 3Y Average Gross Margin

100%

Gross Margin is Increasing

100% > 100%

Negative Operating Margin

-495%

Negative 3Y Average Operating Margin

-563%

Operating Margin is Increasing

-608% > -495%